Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 261 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Colorectal Cancer
Interventions
Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer
Interventions
ADCT-301, Pembrolizumab
Drug · Biological
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
Interventions
TRK-950
Biological
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Gastrointestinal Neoplasms
Interventions
GSK5764227
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Los Alamitos, California • Whittier, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Advanced Adenocarcinoma of the Colon or Rectum
Interventions
FOLFIRI., Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Cancer
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-fluorouracil, Pelvic irradiation
Drug · Radiation
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
41
States / cities
Tucson, Arizona • Melbourne, Florida • Miami, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
intensity-modulated radiation therapy, fluorouracil, oxaliplatin, leucovorin calcium, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
fluorouracil, sodium phenylbutyrate, indomethacin, recombinant interferon gamma
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 21, 2026, 5:36 PM EDT
Conditions
Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced May 21, 2026, 5:36 PM EDT